Naitive Technologies Ltd., a UK-based population health company involved in developing innovative solutions in musculoskeletal care, announced on Thursday that it has entered into a strategic agreement with US-based Parvizi Surgical Innovation (PSI).

Under the agreement, the companies intend to advance the development and clinical deployment of OsteoSight, a new technology engineered for the early identification of low bone mineral density. The partnership aligns Naitive with leading orthopaedic surgeons, providing insights into the requirements and demands of front-line healthcare providers.

OsteoSight uses AI to opportunistically scan through millions of routine X-rays for evidence of low bone mineral density, an early warning sign of osteoporosis. It was granted US FDA Breakthrough Device Designation last year. The collaboration aims to expedite the validation and implementation of OsteoSight within clinical settings, making it more accessible to the millions of people with undiagnosed osteoporosis.

Dr Will Briggs, Naitive CEO, said: "With PSI's support, we're ensuring our technology meets the rigorous standards of clinical care but also seamlessly integrates into real-world orthopaedic workflows. Their leadership in musculoskeletal care, combined with our breakthrough technology, will help us make significant advancements in the early diagnosis and treatment of osteoporosis."